UBS lowered the firm’s price target on AdaptHealth (AHCO) to $12 from $13 and keeps a Buy rating on the shares following the earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
- AdaptHealth price target lowered to $13 from $14 at Canaccord
- AdaptHealth price target lowered to $14 from $16 at Baird
- AdaptHealth Reports Q3 2024 Financial Results
- Morning Movers: GlobalFoundries and Apollo Global gain following Q3 results
- AdaptHealth revises FY24 revenue view to $ $3.22B-$3.26B, consensus $3.28B